When it comes to medicines, value is often in the eye of the beholder.

A new analysis finds that what multiple sclerosis patients value in their medicines is generally overlooked by payers and doctors. As a result, drug companies subsequently disregard what matters most to patients, according to Real Endpoints, a research firm that conducted the analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • i see I now have to look harder to know a story is premium access before clicking through the emails. I clicked through this and the Axovant one only to hit the wall. Feels like I’ve been baited which I’m not happy about.
    I respect good journalism and am willing to pay my part, but even with the deals for the first year and first month free, it feels like I’ll be paying much more than what’s fair for one person given the potential audience of tens of thousands or more. I’ll pay full from day one, if the price feels reasonable given the potential audience size. Otherwise, no.

  • Since the study is funded by PhRMA, pharma’s trade group, I am not sure the results are completely independent.

    • Hello Girish,
      Thanks for the note. Roger Longman has not yet activated his subscription, but I passed along your remark and he forwarded this reply:

      “The results are independent — interpretation, like all interpretations, is subjective. We think our interpretation reflects reality (and indeed very strongly accords with what plenty of others have written), but others might have different points of view. So we’re producing a white paper which will have all the data from the survey, plus the literature review — with bibliography — so readers can come to their own conclusions. ”

      Hope this helps
      ed at pharmalot

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy